BeiGene, Ltd. (6160.HK)
HKD 105.9
(-1.4%)
HKD 105.9
(-1.4%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -881.7 Million USD | 56.0% |
| 2022 | -2 Billion USD | -41.78% |
| 2021 | -1.41 Billion USD | 11.69% |
| 2020 | -1.6 Billion USD | -68.37% |
| 2019 | -950.57 Million USD | -41.08% |
| 2018 | -673.76 Million USD | -623.67% |
| 2017 | -93.1 Million USD | 21.9% |
| 2016 | -119.21 Million USD | -108.78% |
| 2015 | -57.1 Million USD | -212.41% |
| 2014 | -18.27 Million USD | -143.9% |
| 2013 | -7.49 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -120.4 Million USD | 52.06% |
| 2024 Q1 | -251.15 Million USD | 31.67% |
| 2023 Q4 | -367.55 Million USD | -270.63% |
| 2023 Q1 | -348.43 Million USD | 21.76% |
| 2023 Q3 | 215.41 Million USD | 156.52% |
| 2023 Q2 | -381.13 Million USD | -9.39% |
| 2023 FY | -881.7 Million USD | 56.0% |
| 2022 Q4 | -445.33 Million USD | 20.13% |
| 2022 FY | -2 Billion USD | -41.78% |
| 2022 Q3 | -557.55 Million USD | 2.43% |
| 2022 Q2 | -571.44 Million USD | -31.59% |
| 2022 Q1 | -434.27 Million USD | 25.85% |
| 2021 Q1 | 66.49 Million USD | 114.07% |
| 2021 Q2 | -480.34 Million USD | -822.37% |
| 2021 Q3 | -413.85 Million USD | 13.84% |
| 2021 FY | -1.41 Billion USD | 11.69% |
| 2021 Q4 | -585.65 Million USD | -41.51% |
| 2020 FY | -1.6 Billion USD | -68.37% |
| 2020 Q2 | -335.2 Million USD | 7.84% |
| 2020 Q3 | -425.22 Million USD | -26.86% |
| 2020 Q4 | -472.74 Million USD | -11.18% |
| 2020 Q1 | -363.73 Million USD | 6.27% |
| 2019 Q1 | -167.64 Million USD | 37.51% |
| 2019 FY | -950.57 Million USD | -41.08% |
| 2019 Q2 | -85.57 Million USD | 48.96% |
| 2019 Q3 | -307.35 Million USD | -259.19% |
| 2019 Q4 | -388.06 Million USD | -26.26% |
| 2018 FY | -673.76 Million USD | -623.67% |
| 2018 Q4 | -268.25 Million USD | -86.25% |
| 2018 Q3 | -144.03 Million USD | 8.19% |
| 2018 Q2 | -156.88 Million USD | -49.99% |
| 2018 Q1 | -104.59 Million USD | -5.31% |
| 2017 Q2 | -60.54 Million USD | -19.6% |
| 2017 Q1 | -50.62 Million USD | -34.64% |
| 2017 FY | -93.1 Million USD | 21.9% |
| 2017 Q4 | -99.32 Million USD | -184.61% |
| 2017 Q3 | 117.38 Million USD | 293.88% |
| 2016 FY | -119.21 Million USD | -108.78% |
| 2016 Q2 | -24.12 Million USD | -9.65% |
| 2016 Q4 | -37.59 Million USD | -5.93% |
| 2016 Q3 | -35.49 Million USD | -47.13% |
| 2016 Q1 | -22 Million USD | 19.26% |
| 2015 Q4 | -27.25 Million USD | -94.66% |
| 2015 FY | -57.1 Million USD | -212.41% |
| 2015 Q1 | -10.21 Million USD | -172.25% |
| 2015 Q2 | -5.64 Million USD | 44.76% |
| 2015 Q3 | -13.99 Million USD | -148.17% |
| 2014 Q2 | -2.38 Million USD | 0.0% |
| 2014 Q3 | -9.75 Million USD | -309.35% |
| 2014 Q1 | -2.38 Million USD | 0.0% |
| 2014 FY | -18.27 Million USD | -143.9% |
| 2014 Q4 | -3.75 Million USD | 61.56% |
| 2013 FY | -7.49 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 70.87 Million HKD | 1344.015% |
| CK Life Sciences Int'l., (Holdings) Inc. | 17.25 Million HKD | 5211.351% |